Print Digg


Biosyntrx Launches Avantrx

Friday, August 15, 2008

Eye care practices now have a simple, safe and effective formula to offer patients as they strive to address the vast amount of science that links excess weight to an increased risk of developing degenerative eye diseases, including macular degeneration, cataract, glaucoma and diabetic retinopathy.

Avantrx is a revolutionary portion-control hydrogel gastric bulking formula that reduced portion size intake up to 50% in a clinical study, with an average 4-week weight loss of 7.6 lbs. (see study results and safety data under Avantrx scientific rationale file on this web site page).

Avantrx is an ultra-pure, superabsorbent, polyacrylic hydrogel with the ability to absorb up to 1000 times its weight in water. In the stomach, the microbeads released from the professional strength 750 mg capsule are about the size of grains of sugar. They are activated with water to gently expand within a few minutes to the size of grains of rice, filling the stomach with a soft, slippery mass, the volume of a large apple. After a few hours, the slippery gel-like substance safely passes through the GI tract, and is eliminated naturally - without any known harmful side effects.
Professional strength Avantrx differs completely from other gastric-bulking formulas because their expansion ratios are typically much smaller than the totally bio-inert acrylic polymer used in Avantrx.  Other particles smaller than 0.5mm are released into the small bowel or are absorbed very quickly, which makes the satiety potential of other gastric-bulking products no more effective than a glass of water.
The key to the efficacy of Avantrx is that its microbead structure forms large particles (avg. 1.5mm), which are retained by the stomach for hours, thereby modulating the release of gastric hormones like Grehlin, which send messages to the brain that one is hungry, and enhancing an earlier release of gastric hormones like Leptin, which cause one to feel full sooner.

The microbeads are made from a hydrogel polymer specifically developed for use as a temporary pre-meal gastric bulking agent. Polyacrylic hydrogels have been generally recognized as safe for many years and have been used in a wide variety of applications approved by the FDA for ingestion.

The polymer is totally bio-inert, a water-swelling slippery gel-like version of the acrylic polymers used in intraocular lenses.

Always consult your doctor before starting a weight-loss or weight-management program.

Recommended dosage: Professional Strength Avantrx must always be taken with at least 8 oz of water. It works best when taken one to three hours before a meal. If you don’t achieve a sense of fullness when taking one Avantrx capsule, increase the dosage to two capsules with an additional 8 oz of water. Everyone is different, so Avantrx works slightly differently for each individual. A potent full-spectrum multiple is always recommended when on a reduced calorie diet. We recommend Biosyntrx Oculair, or Macula Complete.

Precautions: Do not take more than 2 Avantrx capsules before any meal or more than six capsules a day. Diabetics, pregnant and nursing mothers, children under 18, morbidly obese people, or those with any form of pre-existing gastrointestinal disease or medical condition should consult with their physician before use.

Overdosage: Do not induce vomiting. Call your physician immediately.

Avantrx is manufactured in a GMP facility to meet the same standards for purity required for pharmaceutical products. Avantrx is certified Kosher and BSE Free.

These statements have not been evaluated by the U.S. Food and Drug Administration.

This product is not intended to diagnose, treat, cure or prevent disease.
Ellen Troyer, MT MA
Biosyntrx Chief Research Officer
Voting Member, Council for Responsible Nutrition


The patent-pending hydrogel polymer in professional strength Avantrx (SWELL) was invented by Richard C, Davis, MD.  Dr. Davis was the founder of a number of companies familiar to the ophthalmic and other medical specialty markets. Two of Dr. Davis' companies have been publicly traded. They include OccuLogix and UroQuest.  The Biosyntrx founders, staff and scientific advisory board are delighted to be the company chosen to introduce this amazing technology to the ophthalmic and optometric community. 
Excess weight has been linked to cardiovascular disease, cancer, stroke and Type 2 diabetes, which is now an epidemic in the United States. Therefore, a sensible portion control plan has become a focus of though-leading physicians in every medical specialty.  Over 50 studies are listed in the references below that also link excess weight to degenerative eye disease, which makes weight a problem that will be addressed by thought leading eye care professionals.
      Contact Biosyntrx Corporate office at 800-688-6815 to place Avantrx orders.

Crestpoint Management, LTD instrument announcement:
Moorfields Utility Forceps 2-510-2


Obesity and Eye Disease
1. Measures of obesity and age-related eye diseases. Klein BE, Klein R, Lee KE, Jensen SC. Ophthalmic Epidemiol. 2001 Sep;8(4): 251-62 [abstract]
2. Obesity and eye diseases. Cheung N, Wong TY. Surv Ophthalmol. 2007 Mar-Apr; 52(2);180-95 [abstract]
3. Obesity is a risk factor for eye diseases. Habot-Wilner Z, Belkin M. Harefuah. 2005 Nov;144(11):805-9,821 [abstract]
4. Aging and retinal vascular diseases. Takagi H. Nippon Ganka Gakkai Zasshi. 2007 Mar;111(3):207-30 [abstract]
5. Systematic review of the long-term effects and economic consequences of treatments for obesity and implications for health improvement. Avenell A, Broom J, Brown TJ, et al. Health Technol Assess. 2004 May;8(21): 1-182 [abstract]
6. Dietary approaches that delay age-related diseases. Everitt AV, Hilmer SN, et al. Clin Interv Aging. 2006;1(1):11-31 [abstract]
Excess Weight / Macular Degeneration Studies
1. A study of the relation between body mass index and the incidence of age-related macular degeneration. Moeini HA, Masoudpour H, Ghanbari H. Br J Ophthalmol. 2005 Aug;89(B): 964-6 [abstract]
2. Progression of age-related macular degeneration; association with body mass index, waist circumference, and waist-hip ratio. Seddon JM, Cote J, David N, Rosner B. Arch Ophthalmol. 2003 Jun;121(6): 785-92 [abstract]
3. Body mass index and the incidence of visually significant age-related maculopathy in men. Schaumberg DA, Christen WG, Hankinson SE, Glynn RJ. Arch Ophthalmol. 2001 Sep; 119((): 1259-65. [abstract]
4. Cardiovascular risk factors and age-related macular degeneration: the Los Angeles Latino Eye Study. Fraser-Bell S, Wu J, Klein R, Asen SP, Hooper C, Foong AW, Varma R. Am J Ophthalmol. 2008 Feb;145(2): 308-16 [abstract]
5. Risk factors for the incidence of Advanced Age-Related Macular Degeneration in the Age-Related Eye Disease Study (AREDS) AREDS report no. 19. Clemons TE, Milton RC, Klein R, Seddon JM, Ferris FL 3rd; Age-Related Eye Disease Study Research Group. Ophthalmology. 2005 Apr;112(4):533-9 [abstract]
6. Cardiovascular disease, its risk factors and treatment, and age-related macular degeneration: Women's Health Initiative Sight Exam ancillary study. Klein R, Deng Y, Klein BE, Hyman L, Seddon J, Frank RN, Wallace RB, Hendrix SL, Duppermann DB, Langer RD, Kuller L, Brunner R, Johnson KC, Thomas AM, Hanna M. Am J Ophthalmol. 2007 Mar; 143(3):473-83 [abstract]
7. A prospective study of 2 major age-related macular degeneration susceptibility alleles and interactions with modifiable risk factors. Schaumberg DA, Hankinson SE, Guo Q, Rimm E, Hunter DJ. Arch Ophthalmol. 2007 Jan; 125(1): 55-62 [abstract]
8. Plasma fibrinogen levels, other cardiovascular risk factors, and age-related maculopathy: the Blue Mountain Eye Study. Smith W, Mitchell P, Leeder SR, Wang JJ. Arch Ophthalmol. 1998 May; 116(5): 583-7 [abstract]
9. Predictors of optical density of lutein and zeaxanthin in retinas of older women in the Carotenoids in Age-Related Eye Disease Study, an ancillary study of the Women's Health Initiative. Mares JA, LaRowe TL, Snodderly DM, Moeller SM, Gruber MJ, Kelin ML, Wooten FR, Johnson EJ, Chappell RJ; CAREDS Macular Pigment Study Group and Investigators. Am J Clin Nutr. 2006 Nov;84(5): 1107-22 [abstract]
10. Early age-related maculopathy and risk factors of cardiovascular disease in middle-aged Lithuanian urban population. Paunksnis A, Cimbalas A, Cerniauskiene LR, Luksiene DI, Margeviciene L, Dammarkiene S, Tamosiunas A, Norkus A. Eur J Ophthalmol. 2005 Mar-Apr; 15(2): 255-62 [abstract]
11. Age-related macular degeneration: analysis in two ophthalmological centers in Pernambuco-Brazil. Santos LP, Diniz JR, Leao Ac, Sena MF. Arg Bras Oftalmol. 2005 Mar-Apt;6892):229-33 [abstract]
12. Obesity, lutein metabolism, and age-related macular degeneration: a web of connections. Johnson EJ. Nutr Rev. 2005 Jan;63(1): 9-15 [abstract]
13. The potential role of oxidative stress in the pathogenesis of the age-related macular degeneration (AMD). Drobek-Slowik M, Karczewicz D, Safranow K. Postepy Hig Med Dose 2007;61:28-37 [abstract]
14. Macular Pigment and Percentage of Body Fat. Nolan J, Donovan O, et al. IOVS
2004;45:3940-3950. [abstract]
15. Macular Pigment Density is Reduced in Obese Subjects. Hammond B, Ciulla T, Snodderly D. IOVS 2002;43:47-50 [abstract]
16. The retinal ciliopathies. Adams NA, Awadein A, Tomas HS. Ophthalmic Genet. 2007 Sep;28(3): 113-25. [abstract]
17. Predictors of optical density of lutein and zeaxanthin in retinas of older women in the Carotenoids in Age-Related Eye Disease Study, an ancillary study of the Women's Health Initiative. Mares JA, LaRowe TL, Snodderly DM, et al. Am J Clin Nutr. 2006 Nov;84(5):1107-22 [abstract]
18. Phytochemicals and age-related eye diseases. Rhone M, Basu A, Nutr Rev. 2008 Aug;66(8): 465-72 [abstract]
19. Modifiable risk factors for age-related macular degeneration. Guymer RH, Chong EW. Med J Aust. 2006 May 1;184(9): 455-8 [abstract]
Excess Weight / Cataract Studies
1. Weight status, abdominal adiposity, diabetes, and early age-related lens opacities. Jacuqes PF, Moeller SM, Hankinson SE, et al. Am J Clin Nutr. 2003 Sep;78(3):400-5 [abstract]
2. A longitudinal study of body mass index and lens opacities. The Framingham Studies. Hiller R, Podgor MJ, Sperduto RD, et al. Ophthalmology 1998 Jul;105(7):1244-50 [abstract]
3. Anthropometric status and cataract: the Salisbury Eye Evaluation project. Caulfield LE, West SK, Barron Y, Cid-Ruzafa J. Am J Clin Nutr. 1999 Feb;69(2):237-42 [abstract]
4. Body mass index and age-related cataract; the Shihpai Eye Study. Kuang TM, Tsai SY, et al. Arch Ophthalmol. 2005 Aug;123(8):1109-14 [abstract]
5. Risk factors for nuclear, cortical and posterior subcapsular cataracts in the Chinese population of Singapore: the Tanjong Pagar Survey. Foster PJ, Wong TY, et al. Br J Ophthalmol. 2003 Sep;87(9):1112-20 [abstract]
6. Cataract formation and prevention. Schichi H. Expert Opin Investig Drugs. 2004 Jun;12(6):691-701 [abstract]
7. Ocular changes, risk markers for eye disorders and effects of cataract surgery in elderly people: a study of an urban Swedish population followed from 70 to 97 years of age. Bergman B, Nilsson-Ehle H, Sjostrand J. Acta Ophthalmol Scand. 2004 Apr;82(2): 166-74 [abstract]
8. Relations between cataract and metabolic syndrome and its components. Paunksnis A, Bojarskiene F, et al. Eur J Ophthalmol. 2007 Jul-Aug;17(4):605-14 [abstract]
9. Prevalence and risk factors of lens opacities in the elderly in Cuenca, Spain. Navarro Esteban JJ, Burierrez Leiva JA, et al. Eur J Ophthalmol. 2007 Jan-Feb;17(1):29-37 [abstract]
10. Association of metabolic syndrome components with cataract. Bojarskiene F, Cerniauskiene LR. Medicina (Kaunas). 2006;42(2):115-22 [abstract]
Excess Weight, IOP and Glaucoma Studies
1. Relationship between intraocular pressure and obesity in children. Akinci A, Cetinkaya E, et al. J Glaucoma. 2007 Oct-Nov;16(7):627-30 [abstract]
2. Relationship between intraocular pressure and obesity in Japan. Mori K, Ando F, et al. Int J Epidemiol. 2000 Aug;29(4):661-6 [abstract]
3. Relationship between intraocular pressure and systemic health parameters in a Korean population. Lee JS, Lee SH, Oum BS, et al. Clin Experiment Ophthalmol. 2002 Aug;30(4):237-41 [abstract]
4. Elevated intraocular pressure is associated with insulin resistance and metabolic syndrome.
Oh SW, Lee S, Park C, Kim DJ. Diabetes Metab Res Rev. 2005 Sep-Oct;21(5):434-40 [abstract]
5. Association of life-style with intraocular pressure in middle-aged and older Japanese residents. Yoshida M, Ishikawa M, Kokaze A, et al. Jpn J Ophthalmol. 2003 Mar-Apr; 47(2); 191-8 [abstract]
6. Associations with intraocular pressure in Latinos: the Los Angeles Latino Eye Study. Memarzadeh F, Ying-Dai M, Azen SP, et al. Am J Ophthalmol. 2008 Jul;146(1):69-76 [abstract]
7. The eye and sleep apnea. McNab AA. Sleep Med Rev. 2007 Aug;11(4): 269-76 [abstract]
8. Sleep-disordered breathing and effects on ocular health. Dhillon S, Shapiro CM, Flanagan J. Can J. Ophthalmol. 2007 Apr;42(2); 238-43 [abstract]
9. Exploring the pathogenesis of IIH: An inflammatory perspective. Sinclair AJ, Ball AK, et al. J Neuroimmunol. 2008 Aug 1. [abstract]
10. Profiles of obesity, weight gain, and quality of life in idiopathic intracranial hypertension (pseudotumor cerebri). Daniels AB, Liu BT, Volpe NJ, et al. Am J Ophthalmol. 2007 Apr;143(4):635-41 [abstract]
Excess Weight / Type 2 Diabetic Retinopathy Studies
1. Preventing diabetes in the clinical setting. Burnet DL, Elliott LD, Quinn MT, et al. J Gen Intern Med. 2006 Jan;21(1):84-93 [abstract]
2. Components of the Metabolic Syndrome and Risk of Cardiovascular Disease and Diabetes in Beaver Dam. Klein B, Klein R, Lee K. Diabetes Care 2002 25:1790-1794. [abstract]
3. Association between the Metabolic Syndrome and Retinal Microvascular Signs: The Atherosclerosis Risk in Communities Study. Wong, T, Duncan B, Golden S, Klein, R, et al. IOVS. 2004;45:2949-2945 [abstract]
4. Retinal vascular caliber, cardiovascular risk factors, and inflammation: The Multi-Ethnic Study of Atherosclerosis (MESA). IOVS 2006;47:2341-2350 [abstract]
5. Ten-Year Incidence of Retinal Vein Occlusion in an Older Population. The Blue Mountain Eye Study. Cugati S, Want J, Rochtchina E, et al. Arch Ophthalmology 2006;124:726-732 [abstract]
6. Preventing type 2 diabetes: genes or lifestyle? Weber MB, Narayan KM. Prim Care Diabetes. 2008 Jun;2(2): 65-6 [abstract]
7. Ocular and systemic factors associated with diabetes mellitus in the adult population in rural and urban China. The Beijing Eye Study. Xu L, Xie XW, Wang YX, Jonas JB. Eye 2008 Feb 8. [abstract]
8. Contributions of inflammatory processes to the development of the early stages of diabetic retinopathy. Kern TS. Exp Diabetes Res. 2007;2007:95103 [abstract]
9. Nutrition ad metabolic syndrome. Matia MP, Decumberri Pascual E, Calle Pascual AL. Rev Esp Salud Publica. 2007 Sep-Oct;81(5): 489-505 [abstract]
10. Prediabetes: a position statement from the Australian Diabetes Society and Australian Diabetes Educators Association. Twigg SM, Kamp MC, Davis TM, et al. Med J Aust. 2007 May 7;186(9):461-5 [abstract]
11. Identification and treatment of prediabetes to prevent progression to type 2 diabetes. Fonseca VA. Clin Cornerstone. 2007;8(2):10-8 [abstract]
12. Progress in the prevention of type 2 diabetes. Schernthaner G. Wien Klin Wochenschr. 2003 Nov 28;115(21-22):745-57 [abstract]
13. Eye Disease and the Older Diabetic. Tumosa N. Clin Geriatr Med. 2008 Aug;24(3): 515-527 [abstract]
14. Anterior ischemic optic neuropathy associated with metabolic syndrome. Kosanovic-Jakovic N, Ivanovic B, et al. Arg Bras Oftalmol. 2008 Jan-Feb;71(1):62-6 [abstract]
15. Screening for type 2 diabetes: literature review and economic modelling. Waugh N, Scotland G, et al. Health Technol Assess. 2007 May; 11 (17): 1-125 [abstract]